5'-脱氧氟尿苷用于胃肠道癌和乳腺癌的II期研究
[Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
作者信息
Tominaga T, Kitamura M, Hayashi K, Takahashi I, Kosaki G
出版信息
Gan To Kagaku Ryoho. 1985 Nov;12(11):2172-8.
Clinical effects of daily oral administration of 5'-DFUR were studied in patients with advanced or recurrent gastrointestinal cancer and breast cancer. Cases included 5 gastric cancer, 18 colorectal cancer, 27 breast cancer and 1 malignant melanoma. Out of 38 cases who completed the treatment, CR was observed in 2 and PR in 7, the response rate being 23.7%. Out of 23 cases with breast cancer who completed the treatment, CR was observed in 2 and PR in 6, the response rate being 34.8%. Safety was evaluated in 42 cases and diarrhea was found in 17.1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug.
对晚期或复发性胃肠道癌和乳腺癌患者进行了每日口服5'-DFUR的临床疗效研究。病例包括5例胃癌、18例结直肠癌、27例乳腺癌和1例恶性黑色素瘤。在完成治疗的38例患者中，观察到2例完全缓解（CR），7例部分缓解（PR），缓解率为23.7%。在完成治疗的23例乳腺癌患者中，观察到2例CR，6例PR，缓解率为34.8%。对42例患者进行了安全性评估，发现17.1%的患者出现腹泻；然而，通过减少药物剂量或停药，腹泻很容易得到缓解。
Zotero 插件